Development of a Physiologically-Based Pharmacokinetic Model of the Rat Central Nervous System

Other literature type, Article English OPEN
Badhan, Raj K. Singh ; Chenel, Marylore ; Penny, Jeffrey I. (2014)
  • Publisher: MDPI
  • Journal: Pharmaceutics, volume 6, issue 1, pages 97-136 (issn: 1999-4923, eissn: 1999-4923)
  • Related identifiers: pmc: PMC3978528, doi: 10.3390/pharmaceutics6010097
  • Subject: physiologically-based pharmacokinetic model; blood–brain barrier; cerebrospinal fluid; unbound fraction; brain | physiologically-based pharmacokinetic model | blood–brain barrier | cerebrospinal fluid | unbound fraction | brain | Article

Central nervous system (CNS) drug disposition is dictated by a drug’s physicochemical properties and its ability to permeate physiological barriers. The blood–brain barrier (BBB), blood-cerebrospinal fluid barrier and centrally located drug transporter proteins influence drug disposition within the central nervous system. Attainment of adequate brain-to-plasma and cerebrospinal fluid-to-plasma partitioning is important in determining the efficacy of centrally acting therapeutics. We have developed a physiologically-based pharmacokinetic model of the rat CNS which incorporates brain interstitial fluid (ISF), choroidal epithelial and total cerebrospinal fluid (CSF) compartments and accurately predicts CNS pharmacokinetics. The model yielded reasonable predictions of unbound brain-to-plasma partition ratio (Kpuu,brain) and CSF:plasma ratio (CSF:Plasmau) using a series of in vitro permeability and unbound fraction parameters. When using in vitro permeability data obtained from L-mdr1a cells to estimate rat in vivo permeability, the model successfully predicted, to within 4-fold, Kpuu,brain and CSF:Plasmau for 81.5% of compounds simulated. The model presented allows for simultaneous simulation and analysis of both brain biophase and CSF to accurately predict CNS pharmacokinetics from preclinical drug parameters routinely available during discovery and development pathways.
  • References (149)
    149 references, page 1 of 15

    1. Brodie, B.B.; Kurz, H.; Schanker, L.S. The importance of dissociaton constant and lipid-solubility in influencing the passage of drugs into the cerebrospinal fluid. J. Pharmacol. Exp. Ther. 1960, 1, 20-25.

    2. Elmquist, W.F.; Sawchuk, R.J. Application of microdialysis in pharmacokinetic studies. Pharm. Res. 1997, 3, 267-288.

    3. Hammarlund-Udenaes, M.; Paalzow, L.K.; de Lange, E.C. Drug equilibration across the blood-brain barrier-Pharmacokinetic considerations based on the microdialysis method. Pharm. Res. 1997, 2, 128-134.

    4. Yang, H.; Peters, J.L.; Michael, A.C. Coupled effects of mass transfer and uptake kinetics on in vivo microdialysis of dopamine. J. Neurochem. 1998, 2, 684-692.

    5. Syvanen, S.; Lindhe, O.; Palner, M.; Kornum, B.R.; Rahman, O.; Langstrom, B.; Knudsen, G.M.; Hammarlund-Udenaes, M. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab. Dispos. 2009, 3, 635-643.

    6. Friden, M.; Ljungqvist, H.; Middleton, B.; Bredberg, U.; Hammarlund-Udenaes, M. Improved measurement of drug exposure in the brain using drug-specific correction for residual blood. J. Cereb. Blood Flow Metab. 2010, 1, 150-161.

    7. Cordon-Cardo, C.; OʼBrien, J.P.; Casals, D.; Rittman-Grauer, L.; Biedler, J.L.; Melamed, M.R.; Bertino, J.R. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. USA 1989, 2, 695-698.

    8. Thiebaut, F.; Tsuruo, T.; Hamada, H.; Gottesman, M.M.; Pastan, I.; Willingham, M.C. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: Evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J. Histochem. Cytochem. 1989, 2, 159-164.

    9. Cisternino, S.; Mercier, C.; Bourasset, F.; Roux, F.; Scherrmann, J.-M. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res. 2004, 9, 3296-3301.

    10. Sun, H.; Dai, H.; Shaik, N.; Elmquist, W.F. Drug efflux transporters in the CNS. Adv. Drug Deliv. Rev. 2003, 1, 83-105.

  • Metrics
    No metrics available
Share - Bookmark